Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Toussirot

Showing results (21-30 of 146) with videos related to

Pageof 15
Sort By:
Joint Bone Spine|July 13, 2007
Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an updateEric Toussirot, Jean Roudier
Expert Opinion on Biological Therapy|August 17, 2024
IL-17 inhibitors in axial spondyloarthritis. An overviewEric Toussirot, Renaud Felten
The Journal of Rheumatology|August 19, 2007
Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?Daniel Wendling, Eric Toussirot
Current Opinion in Rheumatology|June 7, 2007
Antiinflammatory treatment with bisphosphonates in ankylosing spondylitisEric Toussirot, Daniel Wendling
Expert Opinion on Pharmacotherapy|February 16, 2005
Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathiesEric Toussirot, Daniel Wendling
Drugs & Aging|June 25, 2005
Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment optionsEric Toussirot, Daniel Wendling
RMD Open|September 29, 2017
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Eric Toussirot, Hubert Marotte
Expert Opinion on Pharmacotherapy|June 24, 2004
Anti-TNF-alpha therapy in ankylosing spondylitisDaniel Wendling, Eric Toussirot
Expert Opinion on Pharmacotherapy|August 24, 2007
The use of TNF-alpha blocking agents in rheumatoid arthritis: an updateEric Toussirot, Daniel Wendling
RMD Open|January 29, 2019
MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?Eric Toussirot, Philippe Saas
Pageof 15

Showing results (21-30 of 146) with videos related to

Sort By:
Pageof 15
Joint Bone Spine|July 13, 2007
Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an updateEric Toussirot, Jean Roudier
Expert Opinion on Biological Therapy|August 17, 2024
IL-17 inhibitors in axial spondyloarthritis. An overviewEric Toussirot, Renaud Felten
The Journal of Rheumatology|August 19, 2007
Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?Daniel Wendling, Eric Toussirot
Current Opinion in Rheumatology|June 7, 2007
Antiinflammatory treatment with bisphosphonates in ankylosing spondylitisEric Toussirot, Daniel Wendling
Expert Opinion on Pharmacotherapy|February 16, 2005
Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathiesEric Toussirot, Daniel Wendling
Drugs & Aging|June 25, 2005
Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment optionsEric Toussirot, Daniel Wendling
RMD Open|September 29, 2017
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Eric Toussirot, Hubert Marotte
Expert Opinion on Pharmacotherapy|June 24, 2004
Anti-TNF-alpha therapy in ankylosing spondylitisDaniel Wendling, Eric Toussirot
Expert Opinion on Pharmacotherapy|August 24, 2007
The use of TNF-alpha blocking agents in rheumatoid arthritis: an updateEric Toussirot, Daniel Wendling
RMD Open|January 29, 2019
MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?Eric Toussirot, Philippe Saas
Pageof 15